Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias-Reference-Cited by-同舟云学术

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias

Published:2016-02-17 Issue:6 Volume:63 Page:997-1005
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Shah Nirali N.¹,Merchant Melinda S.¹,Cole Diane E.¹,Jayaprakash Nalini¹,Bernstein Donna¹,Delbrook Cindy¹,Richards Kelly¹,Widemann Brigitte C.¹,Wayne Alan S.¹²

Affiliation:

1. Pediatric Oncology Branch; Center for Cancer Research, National Cancer Institute; National Institutes of Health (NIH); Bethesda Maryland;

2. Division of Hematology; Oncology and Blood & Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine; University of Southern California; Los Angeles CA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference30 articles.

1. Vincristine neurotoxicity;Weiden;N Engl J Med,1972

2. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906;Bowman;Pediatr Blood Cancer,2011

3. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group;Matloub;Blood,2011

4. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized ewing sarcoma: A report from the Children's Oncology Group;Womer;J Clin Oncol,2012

5. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group;Nachman;J Clin Oncol,1997

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers;Cell Death & Disease;2024-05-11

2. Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology;European Journal of Medical Research;2024-04-09

3. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery;Nature Communications;2024-03-07

4. State of the art in pediatric nanomedicines;Drug Delivery and Translational Research;2024-02-07

5. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells;European Journal of Pharmaceutics and Biopharmaceutics;2024-01